Synthetic glucocorticoids (GCs) potently inhibit the expression of pro-inflammatory genes and are widely used in the treatment of inflammatory diseases. However, some patients are resistant to the therapeutic effects of GCs, and many suffer deleterious side effects from these drugs. Furthermore, the precise mechanisms by which GCs inhibit pro-inflammatory gene expression remain unclear.
Introduction
Endogenous glucocorticoids (GCs) are chiefly synthesised in the adrenal gland, under the regulation of the hypothalamic-pituitary-adrenal (HPA) axis. GC synthesis is initiated by stimulation of the hypothalamus to secrete corticotrophin releasing hormone (CRH). This acts upon the anterior pituitary gland to induce release of adrenocorticotrophic hormone (ACTH). ACTH, in turn, induces the release of GCs such as cortisol from the adrenal cortex (Newton 2000) . One of the major functions of GCs is the suppression of the immune system, for example by inhibiting the expression of numerous pro-inflammatory genes. Since the production of CRH can be induced by pro-inflammatory cytokines (Besedovsky et al. 1986 , Del Rey et al. 1987 , the HPA axis serves as a negative feedback mechanism to limit inflammatory responses to infection. Hence the experimental perturbation of the HPA axis (for example by adrenalectomy) impairs the ability of animals to effectively control inflammation (Masferrer et al. 1992 , Green et al. 1995 , Goujon et al. 1996 , Ruzek et al. 1999 . The HPA axis is also thought to function abnormally in some chronic inflammatory diseases, and in strains of experimental animals which are prone to auto-immunity (Jafarian-Tehrani & Sternberg 2000 , Sternberg 2001 , Crofford 2002 . However, cause and effect can be difficult to disentangle because of the multiple levels of cross-talk between the HPA axis and the immune system. The ability of GCs to inhibit expression of a wide variety of pro-inflammatory genes underlies their use in the treatment of chronic inflammatory diseases such as asthma, Crohn's disease, systemic lupus erythematosis and rheumatoid arthritis. Two poorly understood biological effects limit their clinical use. First, GCs are associated with a number of side effects of varying severity, such as osteoporosis, diabetes, hypertension and Cushing's syndrome. Secondly, a small number of patients are resistant to the therapeutic effects of GCs, and may consequently be difficult to treat (DeRijk & Sternberg 1997 , Loke et al. 2002 . The anti-inflammatory mechanisms of action of corticosteroids have been extensively studied for decades, with a view to understanding and overcoming these clinical problems, for example through the design of novel synthetic GCs.
Positive and negative regulation of gene expression by glucocorticoids
The effects of GCs are mediated by a 777 amino acid receptor, which is a member of the nuclear hormone receptor superfamily (Newton 2000) . In the absence of ligand the glucocorticoid receptor (GR) is retained in the cytoplasm in a complex with a number of proteins, including the large heat shock protein hsp90. Upon ligand binding this complex is disrupted and the GR migrates to the nucleus. The transcriptional induction of genes such as tyrosine amino transferase (TAT) and phosphoenolpyruvate carboxykinase (PEPCK) is dependent upon dimerisation of GR and binding to a palindromic promoter sequence, the glucocorticoid response element (GRE). As described in several recent reviews, GR negatively regulates the expression of pro-inflammatory genes by means of transrepression (Gottlicher et al. 1998 , De Bosscher et al. 2000 , Adcock & Caramori 2001 , Karin & Chang 2001 . In this mechanism, ligand-bound, nuclear GR directly interacts with transcription factors such as nuclear factor kappa B (NF B) and AP1, impairing their ability to induce gene expression. The activation of transcription is dependent upon the recruitment of enzyme complexes which mediate localised chromatin modification such as histone acetylation (Naar et al. 2001 , Roth et al. 2001 , Berger 2002 , Rahman 2002 , and this process appears to be influenced by GR (Ito et al. 2000 (Ito et al. , 2001 . Because NF B is activated by pro-inflammatory stimuli and required for transcriptional activation of very many pro-inflammatory genes (Barnes & Karin 1997 , Caamano & Hunter 2002 , the transrepression mechanism may account for many of the anti-inflammatory effects of GCs. A single amino acid mutation of GR has been described, which impairs GR dimerisation and activation of transcription through GREs. In transfected cells the dimerisation defective mutant (GR dim ) is capable of inhibiting NF B function (Heck et al. 1994 (Heck et al. , 1997 ). More significantly, mice which express only GR dim show no impairment in their antiinflammatory responses to GCs (Reichardt et al. 1998 , 2001 , Tuckermann et al. 1999 . To some extent transrepression and transactivation mechanisms of GR can also be uncoupled using novel 'dissociated' GCs, which are selectively impaired in one or other function (Vayssiere et al. 1997 , Vanden Berghe et al. 1999 , Belvisi et al. 2001 . For example GCs which poorly activate transcription through palindromic GREs retain some ability to transrepress NF B and AP1.
These observations lead to the hypothesis (sometimes stated as fact) that deleterious side effects of GCs are mediated by dimerisation-dependent transcriptional activation by GR, whilst anti-inflammatory effects are mediated by dimerisation-independent transrepression by GR. However, this hypothesis remains open to challenge for a number of reasons. A number of broadly antiinflammatory genes, including the NF B inhibitor I B , lipocortin and interleukin (IL)-1 type II receptor are transcriptionally induced by GCs (Newton 2000) , although their relevance to the anti-inflammatory effects of GCs is disputed. Some GC inducible genes do not possess palindromic GREs, and may be regulated in a manner which does not depend upon GR dimerisation (Diamond et al. 1990 , Cella et al. 1998 , Cha et al. 1998 . Dimerisation-independent GC inducible genes could include important anti-inflammatory mediators, a possibility which might be assessed by expression profiling of GC responses in wild type and GR dim /GR dim mice. Such a study has not yet been reported. Studies using dissociated GCs focus upon well characterised, palindromic GRE-dependent genes such as TAT and PEPCK, and may likewise fail to address atypical GC inducible genes. In any case the selectivity of impairment of transactivation or transrepression achieved with dissociated GCs is often imperfect, cell type-and species-specific. Experiments employing such compounds must be interpreted with caution. Finally, many pro-inflammatory genes are repressed by GCs at a post-transcriptional level, via mRNA destabilisation or inhibition of translation (references in Clark et al. 2003) . These phenomena cannot be accounted for by transrepression, and suggest the existence of an additional anti-inflammatory mechanism of GCs.
Post-transcriptional regulation of pro-inflammatory gene expression
The mRNAs encoding many immune mediators contain adenosine/uridine rich elements (AREs) within their 3 untranslated regions (UTRs) (Caput et al. 1986 , Shaw & Kamen 1986 , Chen & Shyu 1995 . These sequences were initially characterised as destabilising elements which conferred a short mRNA half life, contributing to the rapid responsiveness of gene expression in the immune system. It has subsequently become clear that AREs can also be involved in the dynamic regulation of mRNA stability, notably by the mitogen activated protein kinase (MAPK) p38 signalling pathway (Clark et al. 2003) . This pathway (Fig. 1) is activated by pro-inflammatory stimuli such as IL-1 and tumour necrosis factor (TNF ), bacterial lipopolysaccharide (LPS) and ultraviolet irradiation (Ono & Han 2000) . MAPK p38 itself is activated by phosphorylation of both threonine and tyrosine residues within a Thr-Gly-Tyr motif, catalysed by the dual specificity MAPK kinases, MKK6 or MKK3. The activation of p38 is terminated by removal of one or both of the activating phosphate groups, catalysed by serine/ threonine-specific phosphatases, tyrosine-specific phosphatases or dual specificity phosphatases (which are able to dephosphorylate both the phospho-threonine and the phospho-tyrosine residues). Members of each class of phosphatase are capable of inactivating p38 (Saxena et al. 1998 , Takekawa et al. 1998 , 2000 , Camps et al. 2000 , Keyse 2000 . MAPK p38 activates the kinase MAPKAPK-2 which, in turn, targets the AREs of certain pro-inflammatory mRNAs to bring about their stabilisation (Winzen et al. 1999 , Lasa et al. 2000 , Clark et al. 2003 .
Induction of MAPK phosphatase 1 by glucocorticoids
It is striking that many genes that are positively regulated at a post-transcriptional level by p38 are negatively regulated at the same level by GCs (Table 1) . Prompted by this observation, we investigated the effect of GCs upon the p38 pathway, and showed that dexamethasone destabilised cyclooxygenase 2 (Cox-2) mRNA by inhibiting the function, but not the expression of MAPK p38 (Lasa et al. 2001) . The inhibition of p38 was then shown to be mediated by a phosphatase (Lasa et al. 2002) . We and others demonstrated that dexamethasone induces the expression of MAPK phosphatase 1 (MKP-1), a dual specificity phosphatase which potently inactivates p38 (Kassel et al. 2001 , Chen et al. 2002 , Lasa et al. 2002 . This induction was mediated by the GR and dependent upon ongoing transcription. No other known p38-inactivating phosphatases were significantly induced by dexamethasone, and cells which failed to express MKP-1 also failed to down-regulate p38 activity in response to dexamethasone (Lasa et al. 2002) . In mast cells an additional level of regulation was described, in which GCs inhibited the degradation of MKP-1 (Kassel et al. 2001 ).
The precise mechanisms of regulation of MKP-1 expression and the impact of this additional, non-genomic pathway in cells other than mast cells are not yet clear. Nevertheless, it is likely that MKP-1 plays a role in the inhibition of p38 and the consequent destabilisation of pro-inflammatory mRNAs by GCs.
Transcriptional and post-transcriptional mechanisms of action of glucocorticoids
An important distinction between transcriptional and posttranscriptional mechanisms of inhibition of proinflammatory gene expression is their time dependence. Transrepression can be effective only during the period when the transcription of the pro-inflammatory gene is active. For many pro-inflammatory genes this transcriptional window may be relatively brief. In contrast, the destabilisation of a pro-inflammatory mRNA or the inhibition of its translation may have a profound effect on gene expression even if it occurs some time after the proinflammatory stimulus and the period of active transcription. This distinction is illustrated by the example of a lung epithelial cell line, which expresses the pro-inflammatory mediator Cox-2 in response to IL-1. The synthetic GC, dexamethasone, destabilises Cox-2 mRNA and inhibits Cox-2 expression even if added 10 h after the stimulus. In contrast, the transcriptional inhibitor, actinomycin D, is able to inhibit Cox-2 expression only if added within an hour of the IL-1 stimulus (Newton et al. 1998) . Posttranscriptional repression allows cells to rapidly and specifically switch off gene expression in response to extracellular signals, a property which is invaluable in the context of the immune system (Clark 2000). In a physiological context cells will be recruited to sites of inflammation, exposed to pro-inflammatory stimuli, endogenous or exogenous GCs at different stages. It is arguable that the efficient inhibition of an inflammatory response may require both transcriptional and post-transcriptional mechanisms to block the induction of expression of pro-inflammatory mRNAs, and to rapidly clear pre-existing transcripts. Experimental systems have typically been designed to address either transcriptional or post-transcriptional suppression of proinflammatory gene expression, and do not make clear the relative contributions of these processes in vivo. In fact changes in steady state mRNA have often been ascribed to transcriptional regulation without assessing possible changes in mRNA stability.
Physiological significance of MAPK phosphatase 1 gene expression
The phosphatase MKP-1 preferentially inactivates MAPK p38 and c-Jun N-terminal kinase (JNK) (Franklin & Kraft 1997) , but under some circumstances may also Pro-inflammatory stimuli result in the activation of MKK6, a dual specificity kinase. MKK6 activates p38 by phosphorylating threonine and tyrosine residues within the TGY activation motif. In turn, p38 phosphorylates and activates a number of substrates, including MK2, which is implicated in the post-transcriptional regulation of several pro-inflammatory genes. Because both threonine and tyrosine phosphorylations are required for its full activation, p38 can be inactivated by serine/threonine-specific phosphatases, tyrosine-specific phosphatases or dual specificity phosphatases. MKK6, MAPK kinase 6; MK2, MAPK activated protein kinase 2; S/T P-ase, serine/threonine specific phosphatase; Y P-ase, tyrosine specific phosphatase; DUSP, dual specificity phosphatase; P, phosphate group. dephosphorylate extracellular signal regulated kinase (Erk) (Camps et al. 2000 , Keyse 2000 . Its expression is induced by a remarkable variety of stimuli, including cellular stresses, LPS, pro-inflammatory cytokines and agonists with anti-inflammatory effects, including transforming growth factor (TGF)-, cholera toxin B subunit and cAMP elevating agents (Keyse & Emslie 1992 , Guo et al. 1998 , Burgun et al. 2000 , Valledor et al. 2000 , Chen et al. 2002 , Lasa et al. 2002 , Xiao et al. 2002 . Sustained GC-induced expression of MKP-1 has been demonstrated in HeLa cells (Lasa et al. 2002) , a rat mast cell line (Kassel et al. 2001 ) and a mouse macrophage cell line (Chen et al. 2002) , in all of which it appears to mediate inhibition of MAPK signalling and pro-inflammatory gene expression in response to cell stimulation. As the MAPK pathways are pleiotrophic regulators of gene expression in the immune system (Kracht & Saklatvala 2002) , MKP-1 may be an important negative regulator of many aspects of the inflammatory response. MAPK p38 regulates transcription via factors that include MEF2C, ATF2 and NF B (Treisman 1996 , Ono & Han 2000 , Schmitz et al. 2001 , Vermeulen et al. 2003 , whereas JNK is an activator of AP1 and other transcription factors (Whitmarsh & Davis 1996 , Ip & Davis 1998 , suggesting a potential role for MKP-1 in the inhibition of transcription by GR. However, GCs may suppress JNK activity in the absence of ongoing transcription (Caelles et al. 1997 , Gonzalez et al. 2000 , and the dissociated GC RU38486, which does not induce MKP-1 gene expression (Lasa et al. 2002) , retains some ability to transrepress AP1 (Heck et al. 1994 , Vayssiere et al. 1997 . Induction of MKP-1, therefore, appears to be dispensible for transrepression, yet may provide an additional mechanism for inhibition of transcription by GCs.
As determined in tissue culture systems, the properties of MKP-1 suggest a versatile role for this phosphatase in the negative regulation of immune responses (Chen et al. 2002) . However, several questions remain to be answered before the physiological significance of this phosphatase can be understood. Do GCs inhibit MAPK function and induce MKP-1 expression in vivo, particularly in physiologically relevant cell types such as macrophages, mast cells, gut and lung epithelia? Are other phosphatases induced by GCs in vivo? Is the induction of MKP-1 dependent on GR dimerisation, for example does it occur in mouse cells which express only the dimerisation defective form of the receptor? How does its expression respond to novel, dissociated GCs? Finally, does the absence of MKP-1 significantly impair the anti-inflammatory effects of GCs? The latter question will be most easily addressed by means of antisense or RNA interference technology, or using an MKP-1 knock out mouse line which was described several years ago (Dorfman et al. 1996) . The MKP-1 null mouse develops normally and shows no abnormalities in the regulation of Erk function; however the regulation of p38 and JNK was not examined, nor were the responses to pro-inflammatory stimuli or GCs.
If MKP-1 plays a significant role in the suppression of inflammation by GCs, it follows that GC resistance in some inflammatory disease states could be related to defects in the expression or function of MKP-1. Elevated JNK and p38 activities have been described in inflammatory diseases, and are possible targets for clinical intervention (Badger et al. 1996 , Hallsworth et al. 2001 , Kumar et al. 2001 , Hommes et al. 2002 , Waetzig et al. 2002 . GC resistance in asthma and inflammatory bowel disease may be associated with a failure of GCs to inhibit JNK and p38 (Sousa et al. 1999 , Bantel et al. 2002 . Because these kinases negatively regulate GR function (Rogatsky et al. 1998 , Irusen et al. 2002 , the elevation of MAPK activity could be self-perpetuating. In other words an initial defect in GC-induced MKP-1 expression or activity might increase MAPK activity, impairing GR function and further inhibiting the induction of MKP-1 expression (Fig. 2) . Consequences of the fracture of this regulatory loop might include increases in transcription of proinflammatory genes, or in the stability of the mRNAs produced. Several mechanisms are employed by GCs to inhibit the expression of pro-inflammatory genes, hence there are likely to be several paths to GC insensitivity. The involvement of MKP-1 in these phenomena should become clearer over the next few years. Interestingly, GC-induced osteoporosis in the rat is prevented by sodium orthovanadate, an efficient inhibitor of tyrosine phosphatases, including MKP-1 (Hulley et al. 1998 (Hulley et al. , 2002 . The involvement of MKP-1 in the side effects of GCs may also be worth further investigation.
Note added in proof
It was recently reported that GCs also induce the expression of MKP-1 in osteoblasts (Engelbrecht et al. 2003) . 
